2019
Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center
Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.Peer-Reviewed Original ResearchSmilow Cancer HospitalMultiple myelomaRefractory MMInfusion reactionsSpeakers bureauCancer HospitalReal-word experienceReal-world practice patternsAnti-plasma cell therapyTransplant-eligible patientsYale Cancer CenterInfusion-related reactionsAdverse event profileLeukotriene receptor antagonistsProgression-free survivalRefractory multiple myelomaPatient-reported qualityManagement of patientsOverall response rateJanssen Scientific AffairsClonal plasma cellsExcellent safety profileMulti-center studyDrug combination regimensInfusion reaction rates
2018
Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment
Juthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood 2018, 132: 5810. DOI: 10.1182/blood-2018-99-119418.Peer-Reviewed Original ResearchVenous thromboembolismVTE patientsPrevention of VTESymptoms of VTERecurrent venous thromboembolismDeep venous thrombosisRandomized control trialLong-term managementOnline health educationMost patientsPulmonary embolismAdult patientsHospitalized patientsOncology providersVenous thrombosisHematology clinicCancer HospitalMedication adherenceOutpatient clinicTreatment optionsPatient interviewsPhysician interviewsMalignant hematologyPatient educationPreventable deaths